한빛사 논문
Abstract
Dong-Sung Lee1,2,3,*, Jong-Yeon Shin1,4,*, Peter D. Tonge5, Mira C. Puri5,6, Seungbok Lee1,2,3, Hansoo Park1,2,3, Won-Chul Lee1,4, Samer M.I. Hussein5, Thomas Bleazard7, Ji-Young Yun1,4, Jihye Kim1,4, Mira Li5, Nicole Cloonan8,9, David Wood8, Jennifer L. Clancy10, Rowland Mosbergen11, Jae-Hyuk Yi1, Kap-Seok Yang4, Hyungtae Kim4, Hwanseok Rhee12, Christine A. Wells11,13, Thomas Preiss10,14, Sean M. Grimmond8,15, Ian M. Rogers5,16,17, Andras Nagy5,17,18 & Jeong-Sun Seo1,2,3,4
1 Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul 110-799, Korea. 2 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 110-799, Korea. 3 Department of Biochemistry, Seoul National University College of Medicine, Seoul 110-799, Korea. 4 Life Science Institute, Macrogen Inc., Seoul 153-781, Korea. 5 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5. 6 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5T 3H7. 7 Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PT, UK. 8 Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia. 9 QIMR Berghofer Medical Research Institute, Genomic Biology Lab, 300 Herston Road, Herston, Queensland 4006, Australia. 10 Genome Biology Department, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia. 11 Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland 4072, Australia. 12 Macrogen Bioinformatics Center, Macrogen, Seoul 153-781, Republic of Korea. 13 College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland G12 8TA, UK. 14 Molecular, Structural & Computational Biology Division, Victor Chang Cardiac Research Institute, Sydney, New SouthWales 2010, Australia. 15WolfsonWohl Cancer Research Centre, Institute for Cancer Sciences, University of Glasgow, Bearsden, Glasgow Scotland G61 1BD, UK. 16 Department of Physiology, University of Toronto, Toronto, Ontario, Canada M5T 3H7. 17 Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada M5T3H7. 18 Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada M5T 3H7.
* These authors contributed equally to this work.
Correspondence and requests for materials should be addressed to Jeong-Sun Seo
Abstract
Reprogramming of somatic cells to induced pluripotent stem cells involves a dynamic rearrangement of the epigenetic landscape. To characterize this epigenomic roadmap, we have performed MethylC-seq, ChIP-seq (H3K4/K27/K36me3) and RNA-Seq on samples taken at several time points during murine secondary reprogramming as part of Project Grandiose. We find that DNA methylation gain during reprogramming occurs gradually, while loss is achieved only at the ESC-like state. Binding sites of activated factors exhibit focal demethylation during reprogramming, while ESC-like pluripotent cells are distinguished by extension of demethylation to the wider neighbourhood. We observed that genes with CpG-rich promoters demonstrate stable low methylation and strong engagement of histone marks, whereas genes with CpG-poor promoters are safeguarded by methylation. Such DNA methylation-driven control is the key to the regulation of ESC-pluripotency genes, including Dppa4, Dppa5a and Esrrb. These results reveal the crucial role that DNA methylation plays as an epigenetic switch driving somatic cells to pluripotency.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기